Translational Neurodegeneration最新文献

筛选
英文 中文
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease.
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-12-03 DOI: 10.1186/s40035-024-00450-9
Simon McDowall, Vaishali Bagda, Stuart Hodgetts, Frank Mastaglia, Dunhui Li
{"title":"Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease.","authors":"Simon McDowall, Vaishali Bagda, Stuart Hodgetts, Frank Mastaglia, Dunhui Li","doi":"10.1186/s40035-024-00450-9","DOIUrl":"10.1186/s40035-024-00450-9","url":null,"abstract":"<p><p>Promising therapeutic strategies are being explored to replace or regenerate the neuronal populations that are lost in patients with neurodegenerative disorders. Several research groups have attempted direct reprogramming of astrocytes into neurons by manipulating the expression of polypyrimidine tract-binding protein 1 (PTBP1) and claimed putative converted neurons to be functional, which led to improved disease outcomes in animal models of several neurodegenerative disorders. However, a few other studies reported data that contradict these claims, raising doubt about whether PTBP1 suppression truly reprograms astrocytes into neurons and the therapeutic potential of this approach. This review discusses recent advances in regenerative therapeutics including stem cell transplantations for central nervous system disorders, with a particular focus on Parkinson's and Alzheimer's diseases. We also provide a perspective on this controversy by considering that astrocyte heterogeneity may be the key to understanding the discrepancy in published studies, and that certain subpopulations of these glial cells may be more readily converted into neurons.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"59"},"PeriodicalIF":10.8,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer's disease.
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-11-29 DOI: 10.1186/s40035-024-00451-8
Nerea Gómez de San José, Steffen Halbgebauer, Petra Steinacker, Sarah Anderl-Straub, Samir Abu-Rumeileh, Lorenzo Barba, Patrick Oeckl, Giovanni Bellomo, Lorenzo Gaetani, Andrea Toja, Sára Mravinacová, Sofia Bergström, Anna Månberg, Alberto Grassini, Innocenzo Rainero, Peter Nilsson, Lucilla Parnetti, Markus Otto
{"title":"Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer's disease.","authors":"Nerea Gómez de San José, Steffen Halbgebauer, Petra Steinacker, Sarah Anderl-Straub, Samir Abu-Rumeileh, Lorenzo Barba, Patrick Oeckl, Giovanni Bellomo, Lorenzo Gaetani, Andrea Toja, Sára Mravinacová, Sofia Bergström, Anna Månberg, Alberto Grassini, Innocenzo Rainero, Peter Nilsson, Lucilla Parnetti, Markus Otto","doi":"10.1186/s40035-024-00451-8","DOIUrl":"10.1186/s40035-024-00451-8","url":null,"abstract":"","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"57"},"PeriodicalIF":10.8,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
α-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation. 用于诊断突触核蛋白病的α-突触核蛋白种子扩增测定:临床应用中的创新工具。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-11-21 DOI: 10.1186/s40035-024-00449-2
Yaoyun Kuang, Hengxu Mao, Xiaoyun Huang, Minshan Chen, Wei Dai, Tingting Gan, Jiaqi Wang, Hui Sun, Hao Lin, Qin Liu, Xinling Yang, Ping-Yi Xu
{"title":"α-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation.","authors":"Yaoyun Kuang, Hengxu Mao, Xiaoyun Huang, Minshan Chen, Wei Dai, Tingting Gan, Jiaqi Wang, Hui Sun, Hao Lin, Qin Liu, Xinling Yang, Ping-Yi Xu","doi":"10.1186/s40035-024-00449-2","DOIUrl":"10.1186/s40035-024-00449-2","url":null,"abstract":"<p><p>The spectrum of synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), is characterized by α-synuclein (αSyn) pathology, which serves as the definitive diagnostic marker. However, current diagnostic methods primarily rely on motor symptoms that manifest years after the initial neuropathological changes, thereby delaying potential treatment. The symptomatic overlap between PD and MSA further complicates the diagnosis, highlighting the need for precise and differential diagnostic methods for these overlapping neurodegenerative diseases. αSyn misfolding and aggregation occur before clinical symptoms appear, suggesting that detection of pathological αSyn could enable early molecular diagnosis of synucleinopathies. Recent advances in seed amplification assay (SAA) offer a tool for detecting neurodegenerative diseases by identifying αSyn misfolding in fluid and tissue samples, even at preclinical stages. Extensive research has validated the effectiveness and reproducibility of SAAs for diagnosing synucleinopathies, with ongoing efforts focusing on optimizing conditions for detecting pathological αSyn in more accessible samples and identifying specific αSyn species to differentiate between various synucleinopathies. This review offers a thorough overview of SAA technology, exploring its applications for diagnosing synucleinopathies, addressing the current challenges, and outlining future directions for its clinical use.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"56"},"PeriodicalIF":10.8,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cellular senescence in Alzheimer's disease: from physiology to pathology. 阿尔茨海默病中的细胞衰老:从生理学到病理学。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-11-20 DOI: 10.1186/s40035-024-00447-4
Jing Zhu, Chongyun Wu, Luodan Yang
{"title":"Cellular senescence in Alzheimer's disease: from physiology to pathology.","authors":"Jing Zhu, Chongyun Wu, Luodan Yang","doi":"10.1186/s40035-024-00447-4","DOIUrl":"10.1186/s40035-024-00447-4","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, characterized by the accumulation of Aβ and abnormal tau hyperphosphorylation. Despite substantial efforts in development of drugs targeting Aβ and tau pathologies, effective therapeutic strategies for AD remain elusive. Recent attention has been paid to the significant role of cellular senescence in AD progression. Mounting evidence suggests that interventions targeting cellular senescence hold promise in improving cognitive function and ameliorating hallmark pathologies in AD. This narrative review provides a comprehensive summary and discussion of the physiological roles, characteristics, biomarkers, and commonly employed in vivo and in vitro models of cellular senescence, with a particular focus on various cell types in the brain, including astrocytes, microglia, oligodendrocyte precursor cells, neurons, and endothelial cells. The review further delves into factors influencing cellular senescence in AD and emphasizes the significance of targeting cellular senescence as a promising approach for AD treatment, which includes the utilization of senolytics and senomorphics.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"55"},"PeriodicalIF":10.8,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification. ROCK1 通过控制溶酶体的生物生成和酸化,在注意力缺失症的发病过程中发挥关键作用。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-11-04 DOI: 10.1186/s40035-024-00442-9
Chenghuan Song, Wanying Huang, Pingao Zhang, Jiyun Shi, Ting Yu, Jing Wang, Yongbo Hu, Lanxue Zhao, Rui Zhang, Gang Wang, Yongfang Zhang, Hongzhuan Chen, Hao Wang
{"title":"Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification.","authors":"Chenghuan Song, Wanying Huang, Pingao Zhang, Jiyun Shi, Ting Yu, Jing Wang, Yongbo Hu, Lanxue Zhao, Rui Zhang, Gang Wang, Yongfang Zhang, Hongzhuan Chen, Hao Wang","doi":"10.1186/s40035-024-00442-9","DOIUrl":"10.1186/s40035-024-00442-9","url":null,"abstract":"<p><strong>Background: </strong>Lysosomal homeostasis and functions are essential for the survival of neural cells. Impaired lysosomal biogenesis and acidification in Alzheimer's disease (AD) pathogenesis leads to proteolytic dysfunction and neurodegeneration. However, the key regulatory factors and mechanisms of lysosomal homeostasis in AD remain poorly understood.</p><p><strong>Methods: </strong>ROCK1 expression and its co-localization with LAMP1 and SQSTM1/p62 were detected in post-mortem brains of healthy controls and AD patients. Lysosome-related fluorescence probe staining, transmission electron microscopy and immunoblotting were performed to evaluate the role of ROCK1 in lysosomal biogenesis and acidification in various neural cell types. The interaction between ROCK1 and TFEB was confirmed by surface plasmon resonance and in situ proximity ligation assay (PLA). Moreover, we performed AAV-mediated ROCK1 downregulation followed by immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and behavioral tests to unveil the effects of the ROCK1-TFEB axis on lysosomes in APP/PS1 transgenic mice.</p><p><strong>Results: </strong>ROCK1 level was significantly increased in the brains of AD individuals, and was positively correlated with lysosomal markers and Aβ. Lysosomal proteolysis was largely impaired by the high abundance of ROCK1, while ROCK1 knockdown mitigated the lysosomal dysfunction in neurons and microglia. Moreover, we verified ROCK1 as a previously unknown upstream kinase of TFEB independent of m-TOR or GSK-3β. ROCK1 elevation resulted in abundant extracellular Aβ deposition which in turn bound to Aβ receptors and activated RhoA/ROCK1, thus forming a vicious circle of AD pathogenesis. Genetically downregulating ROCK1 lowered its interference with TFEB, promoted TFEB nuclear distribution, lysosomal biogenesis and lysosome-mediated Aβ clearance, and eventually prevented pathological traits and cognitive deficits in APP/PS1 mice.</p><p><strong>Conclusion: </strong>In summary, our results provide a mechanistic insight into the critical role of ROCK1 in lysosomal regulation and Aβ clearance in AD by acting as a novel upstream serine kinase of TFEB.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"54"},"PeriodicalIF":10.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease. TRPV1 可减轻阿尔茨海默病中 APOE4 依赖性小胶质细胞抗原呈递和 T 细胞浸润。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-10-29 DOI: 10.1186/s40035-024-00445-6
Jia Lu, Kexin Wu, Xudong Sha, Jiayuan Lin, Hongzhuan Chen, Zhihua Yu
{"title":"TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease.","authors":"Jia Lu, Kexin Wu, Xudong Sha, Jiayuan Lin, Hongzhuan Chen, Zhihua Yu","doi":"10.1186/s40035-024-00445-6","DOIUrl":"10.1186/s40035-024-00445-6","url":null,"abstract":"<p><strong>Background: </strong>Persistent innate and adaptive immune responses in the brain contribute to the progression of Alzheimer's disease (AD). APOE4, the most important genetic risk factor for sporadic AD, encodes apolipoprotein E4, which by itself is a potent modulator of immune response. However, little is known about the immune hub that governs the crosstalk between the nervous and the adaptive immune systems. Transient receptor potential vanilloid type 1 (TRPV1) channel is a ligand-gated, nonselective cation channel with Ca<sup>2+</sup> permeability, which has been proposed as a neuroprotective target in AD.</p><p><strong>Methods: </strong>Using Ca<sup>2+</sup>-sensitive dyes, dynamic changes of Ca<sup>2+</sup> in microglia were measured, including exogenous Ca<sup>2+</sup> uptake and endoplasmic reticulum Ca<sup>2+</sup> release. The mRFP-GFP-tagged LC3 plasmid was expressed in microglia to characterize the role of TRPV1 in the autophagic flux. Transcriptomic analyses and flow cytometry were performed to investigate the effects of APOE4 on brain microglia and T cells from APOE-targeted replacement mice with microglia-specific TRPV1 gene deficiency.</p><p><strong>Results: </strong>Both APOE4 microglia derived from induced pluripotent stem cells of AD patients and APOE4-related tauopathy mouse model showed significantly increased cholesterol biosynthesis and accumulation compared to their APOE3 counterparts. Further, cholesterol dysregulation was associated with persistent activation of microglia and elevation of major histocompatibility complex II-dependent antigen presentation in microglia, subsequently accompanied by T cell infiltration. In addition, TRPV1-mediated transient Ca<sup>2+</sup> influx mitigated cholesterol biosynthesis in microglia by suppressing the transcriptional activation of sterol regulatory element-binding protein 2, promoted autophagic activity and reduced lysosomal cholesterol accumulation, which were sufficient to resolve excessive immune response and neurodegeneration in APOE4-related tauopathy mouse model. Moreover, microglia-specific deficiency of TRPV1 gene accelerated glial inflammation, T cell response and associated neurodegeneration in an APOE4-related tauopathy mouse model.</p><p><strong>Conclusions: </strong>The findings provide new perspectives for the treatment of APOE4-dependent neurodegeneration including AD.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"52"},"PeriodicalIF":10.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A tumorigenicity evaluation platform for cell therapies based on brain organoids. 基于脑器官组织的细胞疗法致瘤性评估平台。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-10-29 DOI: 10.1186/s40035-024-00446-5
Jun Xue, Youjun Chu, Yanwang Huang, Ming Chen, Meng Sun, Zhiqin Fan, Yonghe Wu, Liang Chen
{"title":"A tumorigenicity evaluation platform for cell therapies based on brain organoids.","authors":"Jun Xue, Youjun Chu, Yanwang Huang, Ming Chen, Meng Sun, Zhiqin Fan, Yonghe Wu, Liang Chen","doi":"10.1186/s40035-024-00446-5","DOIUrl":"10.1186/s40035-024-00446-5","url":null,"abstract":"<p><strong>Background: </strong>Tumorigenicity represents a critical challenge in stem cell-based therapies requiring rigorous monitoring. Conventional approaches for tumorigenicity evaluation are based on animal models and have numerous limitations. Brain organoids, which recapitulate the structural and functional complexity of the human brain, have been widely used in neuroscience research. However, the capacity of brain organoids for tumorigenicity evaluation needs to be further elucidated.</p><p><strong>Methods: </strong>A cerebral organoid model produced from human pluripotent stem cells (hPSCs) was employed. Meanwhile, to enhance the detection sensitivity for potential tumorigenic cells, we created a glioblastoma-like organoid (GBM organoid) model from TP53<sup>-/-</sup>/PTEN<sup>-/-</sup> hPSCs to provide a tumor microenvironment for injected cells. Midbrain dopamine (mDA) cells from human embryonic stem cells were utilized as a cell therapy product. mDA cells, hPSCs, mDA cells spiked with hPSCs, and immature mDA cells were then injected into the brain organoids and NOD SCID mice. The injected cells within the brain organoids were characterized, and compared with those injected in vivo to evaluate the capability of the brain organoids for tumorigenicity evaluation. Single-cell RNA sequencing was performed to identify the differential gene expression between the cerebral organoids and the GBM organoids.</p><p><strong>Results: </strong>Both cerebral organoids and GBM organoids supported maturation of the injected mDA cells. The hPSCs and immature mDA cells injected in the GBM organoids showed a significantly higher proliferative capacity than those injected in the cerebral organoids and in NOD SCID mice. Furthermore, the spiked hPSCs were detectable in both the cerebral organoids and the GBM organoids. Notably, the GBM organoids demonstrated a superior capacity to enhance proliferation and pluripotency of spiked hPSCs compared to the cerebral organoids and the mouse model. Kyoto Encyclopedia of Genes and Genomes analysis revealed upregulation of tumor-related metabolic pathways and cytokines in the GBM organoids, suggesting that these factors underlie the high detection sensitivity for tumorigenicity evaluation.</p><p><strong>Conclusions: </strong>Our findings suggest that brain organoids could represent a novel and effective platform for evaluating the tumorigenic risk in stem cell-based therapies. Notably, the GBM organoids offer a superior platform that could complement or potentially replace traditional animal-based models for tumorigenicity evaluation.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"53"},"PeriodicalIF":10.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice. 在亨廷顿氏病小鼠大脑中,血浆和脑脊液神经丝蛋白轻链浓度的升高会随着突变亨廷顿蛋白的降低而趋于稳定。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-10-08 DOI: 10.1186/s40035-024-00443-8
Nicholas S Caron, Lauren M Byrne, Fanny L Lemarié, Jeffrey N Bone, Amirah E-E Aly, Seunghyun Ko, Christine Anderson, Lorenzo L Casal, Austin M Hill, David J Hawellek, Peter McColgan, Edward J Wild, Blair R Leavitt, Michael R Hayden
{"title":"Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.","authors":"Nicholas S Caron, Lauren M Byrne, Fanny L Lemarié, Jeffrey N Bone, Amirah E-E Aly, Seunghyun Ko, Christine Anderson, Lorenzo L Casal, Austin M Hill, David J Hawellek, Peter McColgan, Edward J Wild, Blair R Leavitt, Michael R Hayden","doi":"10.1186/s40035-024-00443-8","DOIUrl":"https://doi.org/10.1186/s40035-024-00443-8","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated in clinical trials. Sensitive and dynamic response biomarkers are needed to assess the efficacy of such candidate therapies. Neurofilament light chain (NfL) is a biomarker of neurodegeneration that increases in cerebrospinal fluid (CSF) and blood with progression of HD. However, it remains unknown whether NfL in biofluids could serve as a response biomarker for assessing the efficacy of disease-modifying therapies for HD.</p><p><strong>Methods: </strong>Longitudinal plasma and cross-sectional CSF samples were collected from the YAC128 transgenic mouse model of HD and wild-type (WT) littermate control mice throughout the natural history of disease. Additionally, biofluids were collected from YAC128 mice following intracerebroventricular administration of an antisense oligonucleotide (ASO) targeting the mutant HTT transgene (HTT ASO), at ages both before and after the onset of disease phenotypes. NfL concentrations in plasma and CSF were quantified using ultrasensitive single-molecule array technology.</p><p><strong>Results: </strong>Plasma and CSF NfL concentrations were significantly elevated in YAC128 compared to WT littermate control mice from 9 months of age. Treatment of YAC128 mice with either 15 or 50 µg HTT ASO resulted in a dose-dependent, allele-selective reduction of mHTT throughout the brain at a 3-month interval, which was sustained with high-dose HTT ASO treatment for up to 6 months. Lowering of brain mHTT prior to the onset of regional brain atrophy and HD-like motor deficits in this model had minimal effect on plasma NfL at either dose, but led to a dose-dependent reduction of CSF NfL. In contrast, initiating mHTT lowering in the brain after the onset of neuropathological and behavioural phenotypes in YAC128 mice resulted in a dose-dependent stabilization of NfL increases in both plasma and CSF.</p><p><strong>Conclusions: </strong>Our data provide evidence that the response of NfL in biofluids is influenced by the magnitude of mHTT lowering in the brain and the timing of intervention, suggesting that NfL may serve as a promising exploratory response biomarker for HD.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"50"},"PeriodicalIF":10.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay. 利用胶束辅助种子扩增法超灵敏检测 TDP-43 和淀粉样β蛋白聚集体
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-10-08 DOI: 10.1186/s40035-024-00444-7
Sora Sakamoto, Yuichi Riku, Teiko Komori Nomura, Akio Kimura, Naoki Yamahara, Kazuki Ohuchi, Mari Yoshida, Yasushi Iwasaki, Takayoshi Shimohata, Masatoshi Inden, Ryo Honda
{"title":"Ultrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay.","authors":"Sora Sakamoto, Yuichi Riku, Teiko Komori Nomura, Akio Kimura, Naoki Yamahara, Kazuki Ohuchi, Mari Yoshida, Yasushi Iwasaki, Takayoshi Shimohata, Masatoshi Inden, Ryo Honda","doi":"10.1186/s40035-024-00444-7","DOIUrl":"https://doi.org/10.1186/s40035-024-00444-7","url":null,"abstract":"","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"51"},"PeriodicalIF":10.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model. 在肌萎缩性脊髓侧索硬化症小鼠模型中,抑制 GCN2 可减少突变 SOD1 的聚集和毒性,并延缓疾病进展。
IF 10.8 1区 医学
Translational Neurodegeneration Pub Date : 2024-09-20 DOI: 10.1186/s40035-024-00441-w
Didio Alberto Ortiz, Nuria Peregrín, Miguel Valencia, Rodrigo Vinueza-Gavilanes, Elisa Marín-Ordovas, Roberto Ferrero, María Jesús Nicolás, Gloria González-Aseguinolaza, Montserrat Arrasate, Tomás Aragón
{"title":"GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model.","authors":"Didio Alberto Ortiz, Nuria Peregrín, Miguel Valencia, Rodrigo Vinueza-Gavilanes, Elisa Marín-Ordovas, Roberto Ferrero, María Jesús Nicolás, Gloria González-Aseguinolaza, Montserrat Arrasate, Tomás Aragón","doi":"10.1186/s40035-024-00441-w","DOIUrl":"https://doi.org/10.1186/s40035-024-00441-w","url":null,"abstract":"","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"49"},"PeriodicalIF":10.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信